Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
ACTOPLUS MET XR vs PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in peripheral tissues and reducing hepatic gluconeogenesis. Glimepiride is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Oral, 1 tablet containing pioglitazone 15-30 mg and glimepiride 1-4 mg once daily with the first main meal; maximum daily doses: pioglitazone 45 mg, glimepiride 8 mg.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Pioglitazone: 3–7 hours (parent), 16–24 hours (active metabolites); clinically, once-daily dosing due to metabolite activity. Glimepiride: 5–9 hours (terminal), with prolonged effect in renal impairment.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Pioglitazone: 30% renal (as metabolites, <2% unchanged); 70% fecal/biliary. Glimepiride: 60% renal (metabolites), 40% fecal/biliary.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione